Dr. Gerritsen on a Study of Alisertib in Neuroendocrine Prostate Cancer

Winald Gerritsen, MD, PhD
Published: Thursday, Dec 01, 2016



 
Winald Gerritsen, MD, PhD, professor and medical oncologist, Radboud Medical Center, discusses a phase II study that examined the efficacy and safety of alisertib monotherapy in patients with neuroendocrine prostate cancer, an aggressive, androgen-independent subtype of castration-resistant prostate cancer.
 
Gerritsen explains that the researchers in this study took biopsies from patients who were progressing on different therapies and discovered that, for several of them, their disease was more accurately characterized as neuroendocrine prostate cancer, rather than prostate adenocarcinoma.
 
The results of the study demonstrated that single-agent alisertib yielded a 6-month progression-free survival rate of 16.3% in patients with pathologically confirmed neuroendocrine prostate cancer. Moreover, 2 patients achieved complete response for liver metastases.
 
Twenty-three patients experienced grade 3/4 toxicities, the most common of which were neutropenia, gastrointestinal side effects, fatigue, and febrile neutropenia, anemia, and elevated bilirubin.
 


 
Winald Gerritsen, MD, PhD, professor and medical oncologist, Radboud Medical Center, discusses a phase II study that examined the efficacy and safety of alisertib monotherapy in patients with neuroendocrine prostate cancer, an aggressive, androgen-independent subtype of castration-resistant prostate cancer.
 
Gerritsen explains that the researchers in this study took biopsies from patients who were progressing on different therapies and discovered that, for several of them, their disease was more accurately characterized as neuroendocrine prostate cancer, rather than prostate adenocarcinoma.
 
The results of the study demonstrated that single-agent alisertib yielded a 6-month progression-free survival rate of 16.3% in patients with pathologically confirmed neuroendocrine prostate cancer. Moreover, 2 patients achieved complete response for liver metastases.
 
Twenty-three patients experienced grade 3/4 toxicities, the most common of which were neutropenia, gastrointestinal side effects, fatigue, and febrile neutropenia, anemia, and elevated bilirubin.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x